Sun Pharma acquires Pola Pharma to boost dermatology segment
Sun Pharma recently made an announcement to acquire Japan-based Pola Pharma. The deal, which will help Sun Pharma to strengthen its […]
Sun Pharma recently made an announcement to acquire Japan-based Pola Pharma. The deal, which will help Sun Pharma to strengthen its […]
Yashwant Mahadik has been appointed as President, Global Human Resources, Lupin announced on Tuesday. In an official statement, the drug […]
The Indian Council of Medical Research (ICMR), the apex body for the formulation, coordination and promotion of biomedical research, is […]
Drug major Sun Pharma, an Indian multinational pharmaceutical company headquartered in Mumbai, on July 13 announced a slew of changes […]
According to a recent statement, Kalyanasundaram Subramanian, popularly known as Kal Sundaram, CEO of Taro Pharmaceutical Industries Ltd (Taro), the […]
In focus to bring Ranbaxy facilities to compliance, Sun Pharma sees immense opportunities for expanding its operations in Punjab. According […]
Shares of Sun Pharmaceutical Industries and Ranbaxy Laboratories are trading higher by 2 percent. Sun Pharma stock surged 2 percent […]
Health Application in Demand Straub Clinic and Hospital and Kauai Medical Clinic becomes the first healthcare facility centre to allow […]
Lisinopril recall may not affect the company financially Drug-maker Lupin’s hypertension drug Lisinopril, in the US, recall will not have […]
US approve the sale of low cost medicines by Glenmark Pharmaceuticals this financial year by winning the bids against Sun Pharma, Ranbaxy Laboratories and Dr Reddy.
The FCCB holders, funded by QVT, Sun Pharma and Syndicate Bank, hold bonds worth $42 million in a pharmaceutical company Wockhardt Ltd.
The Mumbai-based firm has received approval from US Food and Drug Administration (USFDA) for its abbreviated new drug application (ANDA) to market a generic version of Schering Plough’s Clarinex tablets, Sun Pharma said in a statement.
Drug maker Sun Pharma recently said it has received a tentative approval from US health regulator to sell a generic version of Crestor tablets, used in the treatment of various heart diseases, in the American market.